Visby Medical has raised more than $100 million in financing to accelerate the development of polymerase chain reaction (PCR) diagnostic technology.
The funds will be used to scale production capacity from tens to hundreds of thousands of tests per month, to expand its product portfolio to include COVID plus influenza A/B combination testing and antimicrobial resistance panels, and to deliver PCR diagnostics to consumers at-home.
